Earnings call transcript: Abbott Q3 2026 results show growth, but shares fall
Abbott Laboratories reported Q3 2026 adjusted earnings of $1.42 per share, matching estimates, on revenue of $13.01 billion, slightly above forecasts. Sales rose 7% and adjusted EPS increased 9% year-over-year. The company cut full-year sales growth guidance to 6% and announced plans to spin off its nutrition business. Shares fell 2.69% in premarket trading.
How this was made
The 30-second read
Why it matters
Guidance cut and spin‑off announcement triggered a 2.7% pre‑market decline, highlighting investor sensitivity to growth expectations.
Market read
The earnings release provides fresh guidance that may prompt short positions or defensive positioning in ABT and related health‑care stocks.
What to watch
Margin expansion and strong diagnostics growth may cushion earnings despite lower sales guidance.
Background
Abbott's Q3 2026 earnings were released, showing solid operational performance but a softened outlook.
Ticker impact
Abbott reported Q3 earnings matching EPS estimates but cut full-year sales growth guidance to 6% and announced a spin‑off of its nutrition business.
likely pressure as the market prices in the lower growth outlook and execution risk of the nutrition spin‑off
Revenue beat was modest; guidance reduction is the primary catalyst driving the 2.7% pre‑market decline.
Market effects
Healthcare sector may see slight pullback as investors reassess growth expectations for diversified med‑tech firms.
U.S. large‑cap health stocks could face modest weakness in early trade.
Limited; impact confined to U.S. equities and health‑care investors.
Counterpoint
The spin‑off could unlock value in the nutrition unit, offering a longer‑term upside if execution succeeds.
Key entities
- companyAbbott Laboratories
U.S. healthcare conglomerate reporting Q3 results and announcing a nutrition business spin‑off.
